Treatment paradigm for an anti-cd19 antibody therapy
AssigneeIncyte Corporation
InventorsStefan Härtle, Frank Striebel
Life of this patent
Estimating the term…
Abstract
The present disclosure provides anti-CD19 antibodies for use in the treatment of various cancers. The anti-CD19 antibody is administered to cancer patients in a specific dose or dosing regimen.
Claims26
An anti-CD19 antibody, for use in the treatment of a cancer wherein said anti-CD19 antibody is administered at a dose of at least 24 mg/kg.
-23. (canceled)
A method of treating a cancer in a human subject in need thereof, the method comprising administering to the human subject an anti-CD19 antibody, wherein the anti-CD19 antibody is administered at a dose of at least 24 mg/kg.
(canceled)
A pharmaceutical composition comprising an anti-CD19 antibody and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is capable of delivering a dose of at least 24 mg/kg of the anti-CD19 antibody when administered to a subject.
Dependencies are inferred from the claim text.